Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$35.28 USD
+0.17 (0.48%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $35.25 -0.03 (-0.09%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
Celldex Therapeutics, Inc. [CLDX]
Reports for Purchase
Showing records 61 - 80 ( 412 total )
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Assets Gaining Important Visibility; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CDX-1140 Differentiation Continues; Impressive SITC Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results; Driving the Personalized Antitumor Strategy Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Nice CDX-3379 Surprise at ASCO; Could Be First Biomarker Driven Approach in HNSCC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results; Continuing to Build Pipeline Profiles
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J